



SAMBA

Santé Mondiale du Bébé à l'Adolescent

Solutions for Advancing Maternal, Baby and Adolescent global health

Publications 2022

1. Adamou R, de Freitas Girardi J, Aka Dago-Akribi H, Dassi Tchoupa Revegue MH, Cacou MC, Moh C, Bouah B, Agbo P, Msellati P, **Raynaud JP, Leroy V**, Sturm G. Étude qualitative sur le vécu de l'annonce du statut VIH aux adolescents en Côte d'Ivoire. *Sante Publique*. 2022.33(5):753-762. [doi: 10.3917/spub.215.0753](#).
2. Amuge P, Lugemwa A, Wynne B, Mujuru HA, Violari A, Kityo CM, Archary M, Variava E, White E, Turner RM, Shakeshaft C, Ali S, Nathoo KJ, Atwine L, Liberty A, Bbuye D, Kaudha E, Mngqibisa R, Mosala M, Mumbiro V, Nanduudu A, Ankunda R, Maseko L, Kekitiinwa AR, Giaquinto C, Rojo P, Gibb DM, Turkova A, Ford D; ODYSSEY Trial Team (**Leroy V** collaborator). Once-daily dolutegravir-based antiretroviral therapy in infants and children living with HIV from age 4 weeks: results from the below 14 kg cohort in the randomised ODYSSEY trial. *Lancet HIV*. 2022.9(9):e638-e648. [doi: 10.1016/S2352-3018\(22\)00163-1](#).
3. Brazier E, Ajeh R, Maruri F, Musick B, Freeman A, Wester CW, Lee MP, Shamu T, Crabtree Ramirez B, d'Almeida M, Wools-Kaloustian K, Kumarasamy N, Althoff KN, Twizere C, Grinsztejn B, Tanser F, Messou E, Byakwaga H, Duda SN, Nash D; International epidemiology Databases to Evaluate AIDS (**Desmonde S, Dahourou D, Leroy V** collaborators). Service delivery challenges in HIV care during the first year of the COVID-19 pandemic: results from a site assessment survey across the global IeDEA consortium. *J Int AIDS Soc*. 2022.25(12):e26036. [doi: 10.1002/jia2.26036](#).
4. Breton G, Diallo OH, Cissé M, Diallo OH, Diallo NA, Soumaoro SA, Camara Y, Montoyo A, Rouzioux C, Koita Y, Peytavin G, Tubiana R, Frange P; ANRS 12344-DIAVINA study group (**Leroy V** collaborator). HIV stigma limits the effectiveness of PMTCT in Guinea: the ANRS 12344-DIAVINA study. *J Antimicrob Chemother*. 2022.77(11):3093-3101. [doi: 10.1093/jac/dkac287](#).
5. Collaborative Initiative for Paediatric HIV Education and Research (CIPHER) Global Cohort Collaboration, **Jesson J**, Crichton S, Quartagno M, Yotebieng M, Abrams EJ, Chokephaibulkit K, Le Coeur S, Aké-Assi MH, Patel K, Pinto J, Paul M, Vreeman R, Davies MA, Ben-Farhat J, Van Dyke R, Judd A, Mofenson L, Vicari M, Seage G 3rd, Bekker LG, Essajee S, Gibb D, Penazzato M, Collins IJ, Wools-Kaloustian K, Slogrove A, Powis K, Williams P, Matshaba M, Thahane L, Nyasulu P, Lukhele B, Mwita L, Kekitiinwa-Rukyalekere A, Wanless S, Goetghebuer T, Thorne C, Warszawski J, Galli L, van Rossum AMC, Giaquinto C, Marczyńska M, Marques L, Prata F, Ene L, Okhonskaya L, Navarro M, Frick A, Naver L, Kahlert C, Volokha A, Chappell E, Pape JW, Rouzier V, Marcelin A, Succi R, Sohn AH, Kariminia A, Edmonds A, Lelo P, Lyamuya R, Ogalo EA, Odhiambo FA, Haas AD, Bolton C, Muhairwe J, Tweya H, Sylla M, D'Almeida M, Renner L, Abzug MJ, Oleske J, Purswani M, Teasdale C, Nuwagaba-Biribonwoha H, Goodall R, **Leroy V**. Growth and CD4 patterns of adolescents living with perinatally acquired HIV worldwide, a CIPHER cohort collaboration analysis. *J Int AIDS Soc*. 2022.25(3):e25871. [doi: 10.1002/jia2.25871](#).
6. **Desmonde S**, Lolekha R, Costantini S, Siraprapasiri T, Frank S, Bakkali T, Benjarattanaporn P, Hou T, Jantaramanee S, Kuttiparambil B, Sethaputra C, Ross J, Ciaranello A. A focused multi-state model to estimate the pediatric and adolescent HIV epidemic in Thailand, 2005-2025. *PLoS One*. 2022.17(11):e0276330. [doi: 10.1371/journal.pone.0276330](#).
7. Edmonds A, Brazier E, Musick BS, Yotebieng M, Humphrey J, Abuogi LL, Adedimeji A, Keiser O, Msukwa M, Carlucci JG, Maia M, Pinto JA, **Leroy V**, Davies MA, Wools-Kaloustian KK; IeDEA. Clinical and programmatic

- outcomes of HIV-exposed infants enrolled in care at geographically diverse clinics, 1997-2021: A cohort study. *PLoS Med.* 2022.19(9):e1004089. [doi: 10.1371/journal.pmed.1004089](https://doi.org/10.1371/journal.pmed.1004089).
8. Renaud F, Mofenson LM, Bakker C, Dolk H, **Leroy V**, Namiba A, Sahin L, Shapiro R, Slogrove A, Thorne C, Vicari M, Low-Beer D, Doherty M. Surveillance of ARV safety in pregnancy and breastfeeding: towards a new framework. *J Int AIDS Soc.* 2022.25 Suppl 2(Suppl 2):e25922. [doi: 10.1002/jia2.25922](https://doi.org/10.1002/jia2.25922).
 9. Revegue MHDT, **Jesson J**, Dago-Akribi HA, **Dahourou DL**, Ogbo P, Moh C, Amoussou-Bouah UB, N'Gbeche MS, Eboua FT, Kouassi EM, Kouadio K, Cacou MC, Horo A, Msellati P, Sturm G, Leroy V; pour la Collaboration leDEA (International epidemiologic Databases to Evaluate AIDS) en Afrique de l'Ouest. Sexual and reproductive health of adolescents living with HIV in pediatric care programs in Abidjan : Structured provision of care and perceptions of health care workers in 2019. *Rev Epidemiol Sante Publique.* 2022.70(4):163-176.[doi: 10.1016/j.respe.2022.04.003](https://doi.org/10.1016/j.respe.2022.04.003).
 10. Rojo P, Moraleda C, Tagarro A, Domínguez-Rodríguez S, Castillo LM, Tato LMP, López AS, Manukyan L, Marcy O, **Leroy V**, Nardone A, Burger D, Bassat Q, Bates M, Moh R, Iroh Tam PY, Mvalo T, Magalhaes J, Buck WC, Sacarlal J, Musiime V, Chabala C, Mujuru HA. Empirical treatment against cytomegalovirus and tuberculosis in HIV-infected infants with severe pneumonia: study protocol for a multicenter, open-label randomized controlled clinical trial. *Trials.* 2022.23(1):531. [doi: 10.1186/s13063-022-06203-1](https://doi.org/10.1186/s13063-022-06203-1).
 11. Saint-Lary L, Dassi Tchoupa Revegue MH, **Jesson J**, Renaud F, Penazzato M, Townsend CL, O'Rourke J, **Leroy V**; WHO HIV Hepatitis and STIs (HHS) Department. Effectiveness and Safety of Atazanavir Use for the Treatment of Children and Adolescents Living With HIV: A Systematic Review. *Front Pediatr.* 2022.10:913105. [doi: 10.3389/fped.2022.913105](https://doi.org/10.3389/fped.2022.913105).
 12. Saint-Lary L, Diallo A, de Monteynard LA, Paul C, Marchand L, Tubiana R, Warszawski J, Mandelbrot L, Rekeciewicz C, Petrov-Sanchez V, Faye A, Sibiude J, Dabis F, Sommet A, **Leroy V**. In utero exposure to antiretroviral drugs and pregnancy outcomes: Analysis of the French ANRS pharmacovigilance database. *Br J Clin Pharmacol.* 2022.88(3):942-964. [doi: 10.1111/bcp.15075](https://doi.org/10.1111/bcp.15075).
 13. Townsend CL, O'Rourke J, Milanzi E, Collins IJ, Judd A, Castro H, Vicari M, **Jesson J**, **Leroy V**, Renaud F, Penazzato M. Effectiveness and safety of dolutegravir and raltegravir for treating children and adolescents living with HIV: a systematic review. *J Int AIDS Soc.* 2022.25(11):e25970. [doi: 10.1002/jia2.25970](https://doi.org/10.1002/jia2.25970).
 14. Turkova A, Waalewijn H, Chan MK, Bollen PDJ, Bwakura-Dangarembizi MF, Kekitiinwa AR, Cotton MF, Lugemwa A, Variava E, Ahimbisibwe GM, Srirompotong U, Mumbiro V, Amuge P, Zuidewind P, Ali S, Kityo CM, Archary M, Ferrand RA, Violari A, Gibb DM, Burger DM, Ford D, Colbers A; ODYSSEY Trial Team (**Leroy V** collaborator). Dolutegravir twice-daily dosing in children with HIV-associated tuberculosis: a pharmacokinetic and safety study within the open-label, multicentre, randomised, non-inferiority ODYSSEY trial. *Lancet HIV.* 2022.9(9):e627-e637. [doi: 10.1016/S2352-3018\(22\)00160-6](https://doi.org/10.1016/S2352-3018(22)00160-6).